Reversible loss of vision due to posterior ischemic optic neuropathy.
Lee
A G
AG
Department of Ophthalmology, Cullen Eye Institute, Baylor College of Medicine, Houston, Tex 77030, USA.
D000208:Acute Disease; D000893:Anti-Inflammatory Agents / Q000627:therapeutic use; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000627:therapeutic use; D001241:Aspirin / Q000627:therapeutic use; D001766:Blindness / Q000209:etiology / Q000503:physiopathology*; D001921:Brain / Q000473:pathology; D005260:Female; D005451:Fluorescein Angiography; D005654:Fundus Oculi; D006801:Humans; D008279:Magnetic Resonance Imaging; D008775:Methylprednisolone / Q000627:therapeutic use; D008875:Middle Aged; D018917:Optic Neuropathy, Ischemic / Q000150:complications* / Q000188:drug therapy / Q000503:physiopathology; D011241:Prednisone / Q000627:therapeutic use; D015354:Vision, Low / Q000209:etiology / Q000503:physiopathology*; D014792:Visual Acuity
D000893:Anti-Inflammatory Agents; D000894:Anti-Inflammatory Agents, Non-Steroidal; D001241:Aspirin; D011241:Prednisone; D008775:Methylprednisolone